Risks of sex hormone therapy in women: important lessons from the transgender woman literature.

R. Quinton

DOI: https://doi.org/10.14423/SMJ.0000000000000269

2015-04-01

Abstract:To the Editor: Dous et al provide a comprehensive and coherent critique of the current evidence in the area of sex hormone therapy1; however, because of the paucity of data, a question of huge interest to clinicians and their patients remains necessarily unaddressed: are different estrogen products associated with different risks and benefits? Even if evidence from the classical postmenopausal literature is scarce, there are nevertheless highly informative data emerging from the analysis of European patient registries for male-to-female transsexuals. Whereas the process of gender transition in the United States is entirely patient funded, the United Kingdom and the Netherlands in particular offer different models of care, based on a preponderance of funding direct from the National Health Service and state-backed insurers, respectively. This enables a highly organized model of care in which progress through the transition requires patients to closely adhere to prescribed treatment and monitoring protocols. Unlike postmenopausal women, who are offered a fixed dose of an estrogen T progesterone product without any titration beyond that for suppression of vasomotor symptoms, male-to-female patients in these two countries receive a carefully titrated dose, balanced against clinical outcomes and with monitoring of serum estrogen levels. This is based upon the need to avoid patient overmedication and on clinician awareness of the huge interindividual differences in bioavailability of the same doses of oral and transdermal estradiol valerate (E2). Current guidance indicates that transgender women can continue taking hormone therapy throughout the lifespan. The first clue that not all estrogens are alike arose from analysis of an Amsterdam male-to-female cohort, amongwhom therewas a threefold greater risk of cardiovascular death among current users receiving ethinylestradiol.3,4 An analysis of a London male-to-female cohort found an eightfold greater risk of venous thromboembolism among users of conjugated equine estrogens than among those receiving oral or transdermal E2. Because these studies are unlikely to be replicated among postmenopausal women, clinicians should consider falling in line with the general principle of endocrine therapy, which is to replace the missing hormone (17A-estradiol, or E2, in the context of any hypogonadal female) wherever possible. By analogy, the World Health Organization has long recommended treating male hypogonadism with native testosterone, rather than with anabolic steroids such as nandrolone.6